← Markets

Gilead Sciences, Inc.

GILD · NASDAQ

Market closed$134.28$-2.02 (-1.48%)After hours $134.30 · +0.01%

Key statistics

Previous close$136.30
Open$137.80
Day high$140.61
Day low$134.10
52-week high$157.29
52-week low$107.75
Market cap166.72B
Volume6.61M
Average volume7.52M
P/E ratio16.04
Forward P/E—
EPS8.37
Dividend yield+2.40%

Market context

Why it moved

Gilead Sciences shares declined as Daiwa Securities cut its price target on the stock, weighing on investor sentiment despite the company's broadly maintained "Moderate Buy" consensus rating and strong pipeline fundamentals.

SifugoldMarketbeatIndiatimesComMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Gilead Sciences declined on Friday, underperforming the broader healthcare sector (XLV), as investor sentiment remained cautious following a mixed Q1 earnings report that saw revenue of $6.96B beat expectations but full-year EPS guidance slashed dramatically due to ~$11.5B in IPR&D charges tied to recent acquisitions. Analysts largely view the guidance cut as non-cash accounting noise rather than a fundamental earnings deterioration, with the HIV franchise growing 10% and Biktarvy patents extended to 2036, though concerns linger around Trodelvy's ASCENT-07 endpoint miss and a 52% YoY drop in Veklury revenue.

-1.482

July 17, 2026Gilead Sciences rose sharply, riding a broad healthcare sector rally sparked by UnitedHealth Group's strong Q2 earnings beat and raised full-year guidance, which lifted sentiment across large-cap pharma and managed care names. The move comes as investors reassess Gilead's near-term outlook after a recent pullback driven by a full-year EPS guidance cut — largely attributed to non-cash IPR&D charges from acquisitions — while the underlying HIV franchise continued to grow 10% in Q1, and the Yeztugo HIV PrEP launch and two upcoming PDUFA decisions remain key catalysts for the second half of 2026.

3.4928

July 16, 2026Gilead Sciences closed modestly higher, outperforming the broader healthcare sector (XLV was roughly flat) amid growing debate over the stock's valuation and pipeline potential. A key narrative is emerging that many investors continue to treat Gilead as a legacy HIV company, even as the biotech prepares up to four drug launches this year — most notably Trodelvy's expanding approvals in first-line metastatic triple negative breast cancer — that could reframe its growth story. Recent Q1 results showed a 4.4% revenue beat but a softer full-year EPS outlook, keeping cost discipline and oncology execution in focus for investors.

1.2765

July 15, 2026Gilead Sciences edged lower, underperforming a broadly mixed healthcare sector, as investors continue to weigh the company's post-Q1 earnings trajectory against its ambitious 2026 pipeline story. Despite a Q1 revenue beat of $6.96 billion (+4.4% YoY) and surging HIV prevention sales, shares have slipped roughly 2% since reporting on a full-year EPS miss. Analyst sentiment remains constructive—Wells Fargo and BMO Capital both reiterate Buy ratings with targets of $165 and $174, respectively—as multiple 2026 drug approvals in oncology and inflammation (Trutakna, Veppanu, Trodelvy's expanded indication) position Gilead for a potential re-rating beyond its HIV-focused identity.

-1.035

July 14, 2026Gilead Sciences closed modestly higher, partially recovering from a sharp 3.7% decline on July 10 triggered by a failed Phase 3 solid tumor trial. Analyst conviction remains strong, with BMO Capital maintaining a Buy and $174 target and Wells Fargo reiterating Buy at $165 on Monday, while broader investor attention is shifting to Gilead's diversification story — multiple 2026 FDA approvals in oncology and inflammation (Trutakna, Trodelvy first-line TNBC, Veppanu, Lumvoa) alongside explosive HIV PrEP growth have analysts setting an average price target of ~$159, well above current levels. The broader healthcare sector faced headwinds from U.S.-Iran tensions lifting oil prices and a mixed market open, though GILD outperformed the XLV sector ETF on the session.

1.2093

July 11, 2026Gilead Sciences fell sharply after a Phase 3 solid tumor clinical trial failure rattled investor confidence, erasing much of the gains built on recent momentum from Trodelvy's FDA approval and Yeztugo's HIV prevention franchise growth. The selloff was compounded by macro headwinds — stronger employment data pushed Treasury yields higher, pressuring biotech broadly — while peer AstraZeneca also declined on its own failed late-stage oncology trial, adding to sector-wide unease. Despite the drop, Morgan Stanley maintains a Buy rating with a $168 price target, and the healthcare sector ETF (XLV) closed modestly lower, suggesting the decline was more company- and biotech-specific than a broad healthcare retreat.

-3.7155

July 10, 2026Gilead Sciences edged lower, giving back a portion of its strong Monday-Tuesday rally that was sparked by HSBC's July 6 upgrade to Buy with a $155 price target, as analysts argued generic competition fears were overdone and highlighted underappreciated upside from long-acting HIV therapies and a growing oncology franchise. Thursday's modest pullback came amid a broader risk-off backdrop driven by renewed U.S.-Iran military strikes threatening the Strait of Hormuz ceasefire, lifting oil prices and stoking inflation concerns — though the healthcare sector (XLV) held relatively firm. With a median analyst price target of $165 and the August 6 earnings report approaching, investor focus remains on lenacapavir's HIV prevention momentum and Trodelvy's 37% Q1 sales growth.

-0.7215

July 9, 2026Gilead Sciences closed modestly lower, edging down as broader market risk-off sentiment — driven by a U.S.-Iran ceasefire collapse and surging oil prices — weighed on equities broadly, while the healthcare sector (XLV) also pulled back. The slight decline follows a strong 5%+ surge on July 7 sparked by HSBC's upgrade to Buy with a $155 target, citing underappreciated long-acting HIV therapies and an oncology pipeline that includes Trodelvy (up 37% YoY in Q1) and lenacapavir-based prevention products. Morgan Stanley also adjusted its price target modestly to $166 (from $168) while maintaining its Overweight rating, and Wall Street consensus remains constructive with a mean target around $161.

-0.396

Simply Wall Street · July 18, 2026Gilead Stock Tops 3 GARP Picks Trading On More Measured ValuationsInvestor's Business Daily · July 17, 2026Gilead Built Its Foundation On HIV; Is It Now In Trouble?24/7 Wall St. · July 15, 2026Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?Reuters · July 14, 2026Congo begins trial of Gilead's experimental antiviral for Ebola BundibugyoSTAT · July 13, 2026AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patentsGilead Sciences · June 24, 2026U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast CancerBusiness Wire · February 10, 2026Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
Benzinga · July 8, 2026Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166
Mt Newswire · July 8, 2026Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating
Benzinga · July 7, 2026Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156
Benzinga · July 6, 2026Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
Benzinga · July 6, 2026Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Mt Newswire · July 6, 2026HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133
Benzinga · July 6, 2026HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155
Benzinga · July 3, 2026If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Peers

S&P 500SPX · $7,457.69-1.01%AbbVie Inc.ABBV · $254.49+0.04%Merck & Co., Inc.MRK · $127.50-0.10%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Johnson & JohnsonJNJ · $253.04+1.23%Pfizer Inc.PFE · $25.05-0.36%Amgen Inc.AMGN · $366.29-1.42%Biogen Inc.BIIB · $205.99-1.40%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Moderna, Inc.MRNA · $61.82-2.11%Novartis AGNVS · $153.76+0.67%Roche Holding AGRO.SW · 339.60+0.83%